Immune-based therapies like atezolizumab (anti-PD-L1) combined with bevacizumab (anti-VEGF) enhance antitumor immunity by blocking PD-1/PD-L1 interactions and normalizing tumor vasculature (12). The gene discussed is CD274; the disease is neoplasm.